- EQS-AFR: MorphoSys AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
- EQS-PVR: MorphoSys AG: Correction of a release from 18/04/2024 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
- EQS-Adhoc: Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
- EQS-Adhoc: Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO
- EQS-News: MorphoSys AG Reports First Quarter 2024 Financial Results
- EQS-News: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
More ▼
Key statistics
On Friday, MorphoSys AG (MOR2:DUS) closed at 16.80, -4.00% below its 52-week high of 17.50, set on May 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.70 |
---|---|
High | 16.80 |
Low | 16.30 |
Bid | 17.00 |
Offer | 17.20 |
Previous close | 16.70 |
Average volume | 0.00 |
---|---|
Shares outstanding | 150.87m |
Free float | 126.33m |
P/E (TTM) | -- |
Market cap | 2.76bn USD |
EPS (TTM) | -3.40 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 18:30 BST.
More ▼